<DOC>
	<DOCNO>NCT00995969</DOCNO>
	<brief_summary>This study look safe effective , novel agent , CT 327 cream treat patient mild moderate psoriasis vulgaris ( PV ) . Patients treat twice daily 8 week specific lesion PV safety symptom PV assess throughout treatment period .</brief_summary>
	<brief_title>CT 327 Treatment Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Age &gt; 18 &lt; 71 year age Able give inform consent Diagnosis mild ( affect &lt; 3 % BSA ) moderate ( affect &lt; 10 % BSA ) Psoriasis Vulgaris , include , baseline visit , two symmetrical lesion least 10 cm2 If female childbearing potential use adequate appropriate form contraception oral contraceptive ; intrauterine device ( IUD ) ; contraceptive injection , implant patch If female , pregnant lactating , intend become pregnant study period one month thereafter Allergy test drug excipients Usage topical corticosteroid topical treatment PV within last two week prior study entry ( include calcineurin inhibitor , topical H1 antihistamine , topical antimicrobial , medicate topical agent ) herbal preparation area select treatment Within 4 week prior study entry , receive systemic treatment psoriasis ( include systemic corticosteroid , nonsteroidal , immunosuppressant , immunomodulating drug , treatment light ) . Received treatment systemic locally act medication might counter influence study aim Presence major medical illness require systemic therapy include cancer Clinical diagnosis bacterial infection skin include impetigo abscess Any clinical relevant ECG abnormality Have clinically significant abnormal clinical laboratory test result screen Received investigational drug take part clinical study within three month prior study History drug , alcohol substance abuse factor limit ability cooperate comply protocol Have concomitant dermatologic medical condition ( ) may interfere investigator 's ability evaluate subject 's response study drug Have immunecompromised status ( know human immunodeficiency virus infection ) Have history malignancy , exclude basal cell carcinoma skin Have active intercurrent infection Suffer erythrodermic psoriasis , psoriasis punctata pustular psoriasis extend chronic stationary form psoriasis Have symptoms clinically significant illness may influence outcome study Have reason , opinion investigator , interfere ability subject participate complete trial , place subject undue risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Mild moderate psoriasis vulgaris</keyword>
</DOC>